1. Home
  2. DLO vs PBLS Comparison

DLO vs PBLS Comparison

Compare DLO & PBLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo DLocal Limited

DLO

DLocal Limited

HOLD

Current Price

$14.38

Market Cap

4.4B

ML Signal

HOLD

Logo Parabilis Medicines Inc. Common Stock

PBLS

Parabilis Medicines Inc. Common Stock

N/A

Current Price

$35.86

Market Cap

3.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
DLO
PBLS
Founded
2013
N/A
Country
Uruguay
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.4B
3.6B
IPO Year
2021
2026

Fundamental Metrics

Financial Performance
Metric
DLO
PBLS
Price
$14.38
$35.86
Analyst Decision
Strong Buy
Analyst Count
8
0
Target Price
$17.25
N/A
AVG Volume (30 Days)
1.6M
405.2K
Earning Date
05-14-2026
N/A
Dividend Yield
1.45%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$41.00
N/A
Revenue Next Year
$26.98
N/A
P/E Ratio
$22.27
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.52
$25.56
52 Week High
$16.78
$36.82

Technical Indicators

Market Signals
Indicator
DLO
PBLS
Relative Strength Index (RSI) 47.79 66.14
Support Level $13.11 $26.42
Resistance Level $14.50 N/A
Average True Range (ATR) 0.49 2.44
MACD -0.12 0.32
Stochastic Oscillator 24.86 86.81

Price Performance

Historical Comparison
DLO
PBLS

About DLO DLocal Limited

DLocal Ltd is focused on making the complex simple, redefining the online payment experience in emerging markets. Through its technology platform, One dLocal, the company enables world-wide enterprise merchants to get paid (pay-in) and to make payments (pay-out) online in a safe and efficient manner. The company earns revenue from fees charged to merchants in connection with payment processing services for cross-border and local payment transactions. The company operates in a single operating segment, which is payment processing. The company's geographical segments include Latin America and Non-Latin America, with a majority of its revenue being generated from Brazil in the Latin America region.

About PBLS Parabilis Medicines Inc. Common Stock

Parabilis Medicines Inc s a clinical-stage biopharmaceutical company. It is focused on the development of medicines targeting protein interactions associated with human diseases. It uses a proprietary platform to develop stabilized helical peptide therapeutics, referred to as Helicons, designed to bind and modulate specific proteins. Its flagship product candidate, zolucatetide, targets the interaction between β-catenin and the T-cell factor (TCF) family of transcription factors within the Wnt/β-catenin signaling pathway, which is associated with cell proliferation and differentiation in multiple cancer types.

Share on Social Networks: